Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03136926
Registration number
NCT03136926
Ethics application status
Date submitted
21/04/2017
Date registered
2/05/2017
Titles & IDs
Public title
Screening Anti-Fungal Exposure in Intensive Care Units
Query!
Scientific title
An International, Multi-centre Prospective Pharmacokinetic Evaluation of Antifungal Drug Exposure in Intensive Care Unit Patients Receiving Conventional Dosing Regimens
Query!
Secondary ID [1]
0
0
SAFE-ICU Protocol V2
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SAFE-ICU
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Antifungal Agents
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Probability of therapeutic target attainment
Query!
Assessment method [1]
0
0
Probability of attainment of therapeutic target associated with optimal efficacy will be determined by measuring the ratio of area under the concentration-time curve (AUC) to the minimum inhibitory concentration (MIC).
Query!
Timepoint [1]
0
0
Seven days
Query!
Secondary outcome [1]
0
0
Mortality
Query!
Assessment method [1]
0
0
30-day mortality
Query!
Timepoint [1]
0
0
30 days
Query!
Eligibility
Key inclusion criteria
* Age = 18
* Critically ill patients requiring ICU care
* Receiving enteral or intravenous therapy of antifungal of interest (triazole, echinocandin, amphotericin) including prophylaxis indication and antifungal therapy started in another unit (wards, operating room) for the same infectious episode
* Availability of suitable intravenous/intra-arterial access to facilitate sample collection
* Written informed consent has been obtained from the patient or their next of kin (according to local regulatory statements for ethical conduct of research at each study site)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Aged < 18 years of age
* Pregnancy
* Consent not obtained (according to local regulatory statements for ethical conduct of research at each study site)
* Diagnosis with human immunodeficiency virus or hepatitis B or C or tuberculosis
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
UNKNOWN
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2018
Query!
Actual
Query!
Sample size
Target
150
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Query!
Recruitment hospital [1]
0
0
Royal Brisbane and Women's Hospital - Brisbane
Query!
Recruitment hospital [2]
0
0
The Royal Melbourne Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
4029 - Brisbane
Query!
Recruitment postcode(s) [2]
0
0
3050 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Louisiana
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Antwerp
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Brussels
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Gent
Query!
Country [5]
0
0
Belgium
Query!
State/province [5]
0
0
Leuven
Query!
Country [6]
0
0
Belgium
Query!
State/province [6]
0
0
Lodelinsart
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Mons
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Ottignies
Query!
Country [9]
0
0
Canada
Query!
State/province [9]
0
0
Manitoba
Query!
Country [10]
0
0
Canada
Query!
State/province [10]
0
0
Nova Scotia
Query!
Country [11]
0
0
Finland
Query!
State/province [11]
0
0
Helsinki
Query!
Country [12]
0
0
Finland
Query!
State/province [12]
0
0
Joensuu
Query!
Country [13]
0
0
Finland
Query!
State/province [13]
0
0
Kuopio
Query!
Country [14]
0
0
Finland
Query!
State/province [14]
0
0
Lahti
Query!
Country [15]
0
0
Finland
Query!
State/province [15]
0
0
Tampere
Query!
Country [16]
0
0
Finland
Query!
State/province [16]
0
0
Turku
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Nimes
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Paris
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Pessac
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Pringy
Query!
Country [21]
0
0
Greece
Query!
State/province [21]
0
0
Athens
Query!
Country [22]
0
0
Hong Kong
Query!
State/province [22]
0
0
Hong Kong SAR
Query!
Country [23]
0
0
Italy
Query!
State/province [23]
0
0
Pisa
Query!
Country [24]
0
0
Italy
Query!
State/province [24]
0
0
Roma
Query!
Country [25]
0
0
Italy
Query!
State/province [25]
0
0
Rome
Query!
Country [26]
0
0
Italy
Query!
State/province [26]
0
0
Torino
Query!
Country [27]
0
0
Malaysia
Query!
State/province [27]
0
0
Johor
Query!
Country [28]
0
0
Malaysia
Query!
State/province [28]
0
0
Kelantan
Query!
Country [29]
0
0
Malaysia
Query!
State/province [29]
0
0
Pahang
Query!
Country [30]
0
0
Malaysia
Query!
State/province [30]
0
0
Kuala Lumpur
Query!
Country [31]
0
0
Malaysia
Query!
State/province [31]
0
0
Serdang
Query!
Country [32]
0
0
Netherlands
Query!
State/province [32]
0
0
Nijmegen
Query!
Country [33]
0
0
Portugal
Query!
State/province [33]
0
0
Coimbra
Query!
Country [34]
0
0
Portugal
Query!
State/province [34]
0
0
Lisbon
Query!
Country [35]
0
0
Portugal
Query!
State/province [35]
0
0
Porto
Query!
Country [36]
0
0
Portugal
Query!
State/province [36]
0
0
Vila Franca de Xira
Query!
Country [37]
0
0
Spain
Query!
State/province [37]
0
0
Barcelona
Query!
Country [38]
0
0
Spain
Query!
State/province [38]
0
0
Valencia
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
The University of Queensland
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Adequate antifungal therapy is a critical determinant of survival in patients admitted to an Intensive Care Unit (ICU) with suspected or proven fungal infections. Critical illness can alter the way human body handles antifungal agents, i.e. how the drugs are distributed in the body and removed from the body. Consequently, these changes can increase the risk of inappropriate antifungal exposure that may lead to adverse consequence on patients' outcome. Developing an evidence-based antifungal dosing guideline is of global significance and should be considered a priority to improving clinical outcomes for patients receiving antifungal agents The aim of the SAFE-ICU Study is to develop optimised antibiotic dosing guidelines for ICU patients with life-threatening infections that account for patient characteristics. This will be achieved through completion of the following aims: i) Describe detailed demographic, clinical and plasma antibiotic concentration-time data in a large ICU patient cohort; ii) Perform a robust statistical analysis of the data collected in Aim 1 to develop an enhanced preliminary prediction algorithm for antifungal dosing. This is a multi-national study and will enrol ICU patients who are prescribed an antifungal agent (fluconazole, voriconazole, posaconazole, isavuconazole, caspofungin, anidulafungin, micafungin or amphotericin B). A minimum of 12 patients per drug will be enrolled across at least 15 countries and up to 80 ICUs. Eligible patients are those admitted to the ICU, who are prescribed an antifungal agent (fluconazole, voriconazole, posaconazole, isavuconazole, caspofungin, anidulafungin, micafungin or amphotericin B). Blood samples will be taken to measure drug concentration. Sampling will occur on two occasions, first during study days 1-3 and then a second time between days 4-7, each over an 8-24 hour period. Blood samples will be taken from a vascular access device already inserted for ICU patient care. Abdominal samples from abdominal indwelling drains already inserted peri operatively will also be collected on these two occasions in the subgroup of patients with intra-abdominal infection. Data on infection, various blood tests and patient specific data will be collected using a structured case report form (CRF). Patients will also be followed up 30 days after enrolment into the study to evaluate 30-day mortality. Collected samples will be frozen and stored locally and then shipped in large batches for processing at Burns Trauma and Critical Care Research Centre, The University of Queensland, Australia. Data analysis for development of antifungal dosing algorithms will also be undertaken at The University of Queensland, Australia.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03136926
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Jason A Roberts, PhD
Query!
Address
0
0
The University of Queensland
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Fekade B Sime, PhD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+61 412 181 027
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03136926